All Stories

  1. Pachydermoperiostosis mimicking the acral abnormalities of acromegaly
  2. Pseudoacromegaly
  3. Coexisting pituitary and non-pituitary gigantism in the same family
  4. Giant Prolactinoma of Young Onset: A Clue to Diagnosis of MEN-1 Syndrome
  5. De novo HNF1 homeobox B mutation as a cause for chronic, treatment-resistant hypomagnesaemia
  6. Emergence of Pituitary Adenoma in a Child during Surveillance: Clinical Challenges and the Family Members’ View in anAIPMutation-Positive Family
  7. AIP and the somatostatin system in pituitary tumours
  8. Fatal Carney Complex in Siblings Due to De Novo Large Gene Deletion
  9. In-frame seven amino-acid duplication in AIP arose over the last 3000 years, disrupts protein interaction and stability and is associated with gigantism
  10. Pituitary Carcinoma in a Patient with an SDHB Mutation
  11. Sporadic pituitary adenomas: the role of germline mutations and recommendations for genetic screening
  12. Genetic Aspects of Pituitary Adenomas
  13. Renin-Angiotensin System Blockade Improves Cardiac Indices in Acromegaly Patients
  14. Social, educational and vocational outcomes in patients with childhood-onset and young-adult-onset growth hormone deficiency
  15. The genetic background of acromegaly
  16. Succinate Dehydrogenase B (SDHB)-Associated Bladder Paragangliomas
  17. Metformin prevents metabolic side effects during systemic glucocorticoid treatment
  18. Diagnostic challenges and management of a patient with acromegaly due to ectopic growth hormone-releasing hormone secretion from a bronchial carcinoid tumour
  19. Systematic Investigation of Expression of G2/M Transition Genes Reveals CDC25 Alteration in Nonfunctioning Pituitary Adenomas
  20. Outcomes of annual surveillance imaging in an adult and paediatric cohort of succinate dehydrogenase B mutation carriers
  21. The clinical, pathological and molecular differences between sparsely and densely granulated somatotroph adenomas
  22. Glioma in an AIP mutation carrier patient
  23. Pseudoacromegaly - a differential diagnostic problem for acromegaly
  24. Olfactory neuroblastoma: a multi centre clinical and pathological review
  25. Metformin alters an anti-proliferative effect of Mitotane in a human adrenocortical cancer (H295R) cell line: preliminary results
  26. The role of the microenvironment in the invasive phenotype of familial pituitary tumours
  27. Polymorphism or mutation? - The role of the R304Q missense AIP mutation in the predisposition to pituitary adenoma
  28. ESR2 mutations in RET mutation-negative familial medullary thyroid carcinoma
  29. Novel Genetic Causes of Pituitary Adenomas
  30. Increased Population Risk ofAIP-Related Acromegaly and Gigantism in Ireland
  31. Gigantism: X-linked acrogigantism and GPR101 mutations
  32. Characterisation of myocardial structure and function in adult-onset growth hormone deficiency using cardiac magnetic resonance
  33. Rapid Proteasomal Degradation of Mutant Proteins Is the Primary Mechanism Leading to Tumorigenesis in Patients With MissenseAIPMutations
  34. Signaling network map of the aryl hydrocarbon receptor
  35. AIP inactivation leads to pituitary enlargement in the Zebrafish embryo model
  36. The Drosophila AIP orthologue is essential for actin cytoskeleton stabilisation and cell adhesion
  37. cAMP-specific PDE4 phosphodiesterases and AIP in the pathogenesis of pituitary tumors
  38. SomaticGPR101Duplication Causing X-Linked Acrogigantism (XLAG)—Diagnosis and Management
  39. Pheochromocytoma Is Characterized by Catecholamine-Mediated Myocarditis, Focal and Diffuse Myocardial Fibrosis, and Myocardial Dysfunction
  40. AIP mutations in young patients with acromegaly and the Tampico Giant: the Mexican experience
  41. Clinicopathologic features of familial pituitary adenomas
  42. Cancerous leptomeningitis and familial congenital hypopituitarism
  43. AIP and the somatostatin signalling in pituitary tumours
  44. Can immediate postoperative random growth hormone levels predict long-term cure in patients with acromegaly?
  45. Endocrine Tumor Genetics: Challenging Issues
  46. Glucagon-like peptide 1 in the pathophysiology and pharmacotherapy of clinical obesity
  47. Diagnosis of Acromegaly
  48. Clinical Features of Acromegaly☆
  49. Patient-reported outcomes of parenteral somatostatin analogue injections in 195 patients with acromegaly
  50. Additive Anti-Tumor Effects of Lovastatin and Everolimus In Vitro through Simultaneous Inhibition of Signaling Pathways
  51. Factors predicting pasireotide responsiveness in somatotroph pituitary adenomas resistant to first-generation somatostatin analogues: an immunohistochemical study
  52. Childhood somatotroph pituitary adenomas due to aryl hydrocarbon receptor interacting protein (AIP) gene mutations
  53. Pegvisomant treatment for X-linked acrogigantism syndrome
  54. Achieving a consensus on managing idiopathic thickening of the pituitary stalk through a national multidisciplinary forum, meeting virtually
  55. In vitroeffects of Imatinib on somatotrophinoma cell line
  56. Silencing of aryl hydrocarbon receptor protein (AIP) up-regulates the small Rho GTPase, CDC42
  57. Novel targeted treatment combinations for malignant neuroendocrine tumour olfactory neuroblastoma
  58. Potential molecular mechanism of AIP-mediated cellular invasion
  59. The effect of AIP on AHR transcriptional activity: implications forAIPmutations pathogenicity
  60. Investigation of the invasive phenotype of AIP-mutated pituitary adenomas
  61. The epidemiology of pituitary adenomas in Iceland, 1955–2012: a nationwide population-based study
  62. Histopathology and molecular characterisation of intrauterine-diagnosed congenital craniopharyngioma
  63. Landscape of Familial Isolated and Young-Onset Pituitary Adenomas: Prospective Diagnosis inAIPMutation Carriers
  64. The effects of chronic candesartan treatment on cardiac and hepatic adenosine monophosphate-activated protein kinase in rats submitted to surgical stress
  65. Prostatic hyperplasia in acromegaly
  66. Treatment-resistant pediatric giant prolactinoma and multiple endocrine neoplasia type 1
  67. The Gene of the Ubiquitin-Specific Protease 8 Is Frequently Mutated in Adenomas Causing Cushing's Disease
  68. 15 YEARS OF PARAGANGLIOMA: The association of pituitary adenomas and phaeochromocytomas or paragangliomas
  69. Metabolic comorbidities in Cushing's syndrome
  70. Ghrelin
  71. Studying Cat (Felis catus) Diabetes: Beware of the Acromegalic Imposter
  72. The ubiquitin-specific protease 8 gene is frequently mutated in adenomas causing Cushing's disease
  73. Pituitary apoplexy in GH-deficient adults treated with GH - a KIMS database retrospective study
  74. Safety and Efficacy of Oral Octreotide in Acromegaly: Results of a Multicenter Phase III Trial
  75. Excessive Growth Hormone Expression in Male GH Transgenic Mice Adversely Alters Bone Architecture and Mechanical Strength
  76. Kallmann syndrome patient with gender dysphoria, multiple sclerosis, and thrombophilia
  77. Heterogeneous Genetic Background of the Association of Pheochromocytoma/Paraganglioma and Pituitary Adenoma: Results From a Large Patient Cohort
  78. Regulation of Aryl Hydrocarbon Receptor Interacting Protein (AIP) Protein Expression by MiR-34a in Sporadic Somatotropinomas
  79. Evaluation of genotype–phenotype relationships in patients referred for endocrine assessment in suspected Pendred syndrome
  80. Prostatic hyperplasia in acromegaly, a myth or reality: a case–control study
  81. GH deficiency after traumatic brain injury: improvement in quality of life with GH therapy: analysis of the KIMS database
  82. An unusual case of an ACTH-secreting macroadenoma with a germline variant in the aryl hydrocarbon receptor-interacting protein (AIP) gene
  83. Multi-parametric cardiovascular magnetic resonance imaging detects subclinical myocardial involvement in patients diagnosed with phaeochromocytoma
  84. A 25-Year-Old Woman with Headache and Joint Pain
  85. Clinical profile and outcome of patients with acromegaly according to the 2014 consensus guidelines: Impact of a multi-disciplinary team
  86. The role of ghrelin in weight-regulation disorders: Implications in clinical practice
  87. Sequence analysis of the catalytic subunit of PKA in somatotroph adenomas
  88. Low rate of germline AIP mutations in patients with apparently sporadic pituitary adenomas before the age of 40: a single-centre adult cohort
  89. Adrenal cancer in neurofibromatosis type 1: case report and DNA analysis
  90. Paediatric pituitary adenomas: rare, complex, and by no means benign
  91. Common Genetic Variants of the Human Steroid 21-Hydroxylase Gene (CYP21A2) Are Related to Differences in Circulating Hormone Levels
  92. Combination of 13-CisRetinoic Acid and Lovastatin: Marked Antitumor Potential In Vivo in a Pheochromocytoma Allograft Model in Female Athymic Nude Mice
  93. Effects of Long-term Growth Hormone Replacement in Adults With Growth Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
  94. 122 Cardiac Abnormalities are Common in Patients Diagnosed with Phaeochromocytoma as Detected by Cardiovascular Magnetic Resonance Imaging
  95. Pituitary blastoma: a pathognomonic feature of germ-line DICER1 mutations
  96. Human AIP gene rescue lethality in a Drosophila melanogaster knockout model of AIP orthologue
  97. The anti-proliferative effect of anti-EGFR tyrosine kinase inhibitor in combination with mitotane on H295R adrenocortical cancer cells
  98. Clinical Experience in the Screening and Management of a Large Kindred With Familial Isolated Pituitary Adenoma Due to an Aryl Hydrocarbon Receptor Interacting Protein (AIP) Mutation
  99. Analysis of the AIP gene promoter
  100. Kallmann syndrome, gender dysphoria, thrombophilia and multiple sclerosis: a complex case report
  101. High incidence of cardiac involvement in patients diagnosed with phaeochromocytoma: a clinical study using cardiovascular magnetic resonance imaging
  102. RET mutation negative familial medullary thyroid carcinoma: four families and literature review
  103. Pre-clinical assessment of the impact of Erlotinib on adrenocortical cancer cells proliferation
  104. Epidemiology and etiopathogenesis of pituitary adenomas
  105. Metformin—mode of action and clinical implications for diabetes and cancer
  106. Preface
  107. Familial pituitary tumors
  108. Characterization of SNARE Proteins in Human Pituitary Adenomas: Targeted Secretion Inhibitors as a New Strategy for the Treatment of Acromegaly?
  109. MicroRNAs: Suggested role in pituitary adenoma pathogenesis
  110. Effects of smoking cessation on  -cell function, insulin sensitivity, body weight, and appetite
  111. The CB1 receptor mediates the peripheral effects of ghrelin on AMPK activity but not on growth hormone release
  112. CB1 receptor mediates the effects of glucocorticoids on AMPK activity in the hypothalamus
  113. A Comprehensive Next Generation Sequencing–Based Genetic Testing Strategy To Improve Diagnosis of Inherited Pheochromocytoma and Paraganglioma
  114. Fasting and postprandial liver glycogen content in patients with type 1 diabetes mellitus after successful pancreas-kidney transplantation with systemic venous insulin delivery
  115. Novel pathway for somatostatin analogs in patients with acromegaly
  116. GH excess in bGH transgenic mice adversely affects bone density, architecture and quality
  117. AIP (aryl hydrocarbon receptor interacting protein)
  118. Gene expression profiling of familial and sporadic pituitary adenomas
  119. Genetic and clinical characteristics of Serbian FIPA families
  120. Drosophila melanogasteras a model organism to study aryl hydrocarbon receptor interacting protein gene function
  121. A Novel Mutation in the Upstream Open Reading Frame of the CDKN1B Gene Causes a MEN4 Phenotype
  122. Familial Pituitary Adenomas
  123. Genes and giants
  124. De Novo HNF1b mutation as a cause for chronic treatment-resistant hypomagnesaemia
  125. Excessive GH expression in bGH transgenic mice adversely alters bone architecture and quality
  126. The role of microRNA miR-34a in the regulation of aryl hydrocarbon receptor interacting protein
  127. Invasion signature' revealed by the analysis of AIP positive and AIP mutation negative human pituitary adenomas
  128. Creation of a locus-specific database for AIP mutations
  129. Genetics of the Ghrelin System
  130. Genetics of Pituitary Adenomas
  131. Ghrelin and cannabinoids require the ghrelin receptor to affect cellular energy metabolism
  132. Structure of the TPR Domain of AIP: Lack of Client Protein Interaction with the C-Terminal α-7 Helix of the TPR Domain of AIP Is Sufficient for Pituitary Adenoma Predisposition
  133. Familial isolated pituitary adenomas: An emerging clinical entity
  134. ACTH-secreting Crooke cell carcinoma of the pituitary
  135. Genetic studies in a coexistence of acromegaly, pheochromocytoma, gastrointestinal stromal tumor (GIST) and thyroid follicular adenoma
  136. 2.7 Expression of a subset of microRNAs in clinically non-functioning pituitary adenomas correlates with tumor size
  137. Familial pituitary adenomas – who should be tested for AIP mutations?
  138. Somatostatin Analogs Modulate AIP in Somatotroph Adenomas: The Role of the ZAC1 Pathway
  139. MicroRNA miR-107 is overexpressed in pituitary adenomas and inhibits the expression of aryl hydrocarbon receptor-interacting protein in vitro
  140. Oncogene-induced senescence in pituitary adenomas and carcinomas
  141. Combined blockade of signalling pathways shows marked anti-tumour potential in phaeochromocytoma cell lines
  142. Mice lacking AMP-activated protein kinase  1 catalytic subunit have increased bone remodelling and modified skeletal responses to hormonal challenges induced by ovariectomy and intermittent PTH treatment
  143. Expression of guanylyl cyclase-B (GC-B/NPR2) receptors in normal human fetal pituitaries and human pituitary adenomas implicates a role for C-type natriuretic peptide
  144. Prostaglandin transporter mutations cause pachydermoperiostosis with myelofibrosis
  145. Genetic analysis in a patient presenting with meningioma and familial isolated pituitary adenoma (FIPA) reveals selective involvement of the R81X mutation of the AIP gene in the pathogenesis of the pituitary tumor
  146. Modifications in basal and stress-induced hypothalamic AMP-activated protein kinase (AMPK) activity in rats chronically treated with an angiotensin II receptor blocker
  147. Ghrelin Regulation of AMPK in the Hypothalamus and Peripheral Tissues
  148. Measurement of AMP-Activated Protein Kinase Activity and Expression in Response to Ghrelin
  149. Cardiovascular changes in patients with adult-onset growth hormone deficiency assessed by CMR
  150. Cardiovascular changes in patients with acromegaly assessed by CMR
  151. Genetic studies on the ghrelin, growth hormone secretagogue receptor (GHSR) and ghrelin O-acyl transferase (GOAT) genes
  152. The Immunophilin-Like Protein XAP2 Is a Negative Regulator of Estrogen Signaling through Interaction with Estrogen Receptor α
  153. Ghrelin in obesity and endocrine diseases
  154. miR-107 Is Overexpressed in Pituitary Adenomas and Inhibits the Expression of Aryl Hydrocarbon Receptor-Interacting Protein (AIP)
  155. Familial isolated pituitary adenoma syndrome
  156. Specific electrocardiographic features associated with Cushing’s disease
  157. AIP and its interacting partners
  158. WITHDRAWN: Ghrelin in obesity and endocrine diseases
  159. The ghrelin/GOAT/GHS-R system and energy metabolism
  160. AIPMutation in Pituitary Adenomas in the 18th Century and Today
  161. 2.3.11 Acromegaly
  162. The expression of ghrelin O-acyltransferase (GOAT) in human tissues
  163. Mechanisms of metformin action on glucose transport and metabolism in human adipocytes
  164. MicroRNA profile indicates downregulation of the TGFβ pathway in sporadic non-functioning pituitary adenomas
  165. Familial isolated pituitary adenomas experience at a single center: clinical importance of AIP mutation screening
  166. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNA in Human Sporadic Pituitary Adenomas
  167. AIP gene and familial isolated pituitary adenomas
  168. Cyclins and their related proteins in pituitary tumourigenesis
  169. Role of the aryl hydrocarbon receptor-interacting protein in familial isolated pituitary adenoma
  170. Down-Regulation of Wee1 Kinase by a Specific Subset of microRNAs in Human Sporadic Pituitary Adenomas
  171. Alterations in Adipose Tissue during Critical Illness
  172. Treatment of acromegaly
  173. AMP-activated protein kinase (AMPK) activation regulates in vitro bone formation and bone mass
  174. Clinical, genetic and molecular characterization of patients with familial isolated pituitary adenomas (FIPA)
  175. AMP-activated protein kinase (AMPK) regulates in vitro bone formation and bone mass in vivo
  176. MicroRNA expression in ACTH-producing pituitary tumors: up-regulation of microRNA-122 and -493 in pituitary carcinomas
  177. Characterization of aryl hydrocarbon receptor interacting protein (AIP) mutations in familial isolated pituitary adenoma families
  178. Ghrelin’s Role as a Major Regulator of Appetite and Its Other Functions in Neuroendocrinology
  179. Molecular Genetics of the Aip Gene in Familial Pituitary Tumorigenesis
  180. PL10 The curious case of ghrelin
  181. Analysis of IMP3 Expression in Normal and Neoplastic Human Pituitary Tissues
  182. Cannabinoids for clinicians: the rise and fall of the cannabinoid antagonists
  183. AMPK as a mediator of hormonal signalling
  184. Activation of RAF/MEK/ERK and PI3K/AKT/mTOR pathways in pituitary adenomas and their effects on downstream effectors
  185. The role of ghrelin and ghrelin-receptor gene variants and promoter activity in type 2 diabetes
  186. Recent Clinical and Pathophysiological Advances in Non-Functioning Pituitary Adenomas
  187. Association Studies onGhrelinandGhrelin ReceptorGene Polymorphisms With Obesity
  188. Shedding light on the intricate puzzle of ghrelin's effects on appetite regulation
  189. AIP, a Protein Mutated in Familial Acromegaly, Plays a Role in the Regulation of Cell Proliferation and Shows Cell-Type Specific Subcellular Localisation
  190. Assessment of p27 (cyclin‐dependent kinase inhibitor 1B) and aryl hydrocarbon receptor‐interacting protein (AIP) genes in multiple endocrine neoplasia (MEN1) syndrome patients without any detectable MEN1 gene mutations
  191. Familial Isolated Pituitary Adenomas
  192. Familial Isolated Pituitary Adenomas
  193. A Genetic Study of the Ghrelin and Growth Hormone Secretagogue Receptor (GHSR) Genes and Stature
  194. STOP AKTING TO TREAT ENDOCRINE TUMOURS
  195. The Yin and Yang of the Ghrelin Gene Products
  196. The potential role of D2 dopamine receptors as a target in the management of neuroendocrine tumors
  197. Changes in Adenosine 5′-Monophosphate-Activated Protein Kinase as a Mechanism of Visceral Obesity in Cushing’s Syndrome
  198. Ghrelin Receptor Gene Polymorphisms and Body Size in Children and Adults
  199. Protein western array analysis in human pituitary tumours: insights and limitations
  200. The Role of the Aryl Hydrocarbon Receptor-Interacting Protein Gene in Familial and Sporadic Pituitary Adenomas
  201. AMP-activated protein kinase mediates glucocorticoid-induced metabolic changes: a novel mechanism in Cushing's syndrome
  202. Somatostatin analogues in the control of neuroendocrine tumours: efficacy and mechanisms
  203. The role of somatostatin analogues in the treatment of neuroendocrine tumours
  204. HLA-DQ3 is a probable risk factor for CMV infection in high-risk kidney transplant patients
  205. The Orexigenic Effect of Ghrelin Is Mediated through Central Activation of the Endogenous Cannabinoid System
  206. The Role of AMP-Activated Protein Kinase in Obesity
  207. Octreotide and the mTOR Inhibitor RAD001 (Everolimus) Block Proliferation and Interact with the Akt-mTOR-p70S6K Pathway in a Neuro-Endocrine Tumour Cell Line
  208. Contents / Foreword / Preface
  209. A new variation in the promoter region, the −604 C>T, and the Leu72Met polymorphism of the ghrelin gene are associated with protection to insulin resistance
  210. Metabolic and hormonal changes during the refeeding period of prolonged fasting
  211. Examining the Candidacy of Ghrelin as a Gene Responsible for Variation in Adult Stature in a United Kingdom Population with Type 2 Diabetes
  212. Ghrelin in neuroendocrine organs and tumours
  213. A mutation and expression analysis of the oncogene BRAF in pituitary adenomas
  214. Ghrelin, the peripheral hunger hormone
  215. Appetite and Metabolic Effects of Ghrelin and Cannabinoids: Involvement of AMP-Activated Protein Kinase
  216. The Farnesoid X Receptor Is Expressed in Breast Cancer and Regulates Apoptosis and Aromatase Expression
  217. PPAR-? expression in pituitary tumours and the functional activity of the glitazones: evidence that any anti-proliferative effect of the glitazones is independent of the PPAR-? receptor
  218. Macro- and micronutrient losses and nutritional status resulting from 44 days of total fasting in a non-obese man
  219. Effect of Gastric Bypass and Gastric Banding on Proneurotensin Levels in Morbidly Obese Patients
  220. Somatostatin analogues stimulate p27 expression and inhibit the MAP kinase pathway in pituitary tumours
  221. Expanding role of AMPK in endocrinology
  222. Ghrelin and cardiovascular health
  223. Refeeding David Blaine — Studies after a 44-Day Fast
  224. Differential gene expression in pituitary adenomas by oligonucleotide array analysis
  225. Enhanced protein kinase B/Akt signalling in pituitary tumours
  226. Fasting and Postprandial Hyperghrelinemia in Prader-Willi Syndrome Is Partially Explained by Hypoinsulinemia, and Is Not Due to Peptide YY3–36Deficiency or Seen in Hypothalamic Obesity Due to Craniopharyngioma
  227. Cannabinoids and Ghrelin Have Both Central and Peripheral Metabolic and Cardiac Effects via AMP-activated Protein Kinase
  228. A HIF1α Regulatory Loop Links Hypoxia and Mitochondrial Signals in Pheochromocytomas
  229. Striant™ SR: a novel, effective and convenient testosterone therapy for male hypogonadism
  230. Akting and Cycling: A Tale of the Pituitary
  231. Theobromine inhibits sensory nerve activation and cough
  232. The cannabinoid CB1 receptor antagonist SR141716 blocks the orexigenic effects of intrahypothalamic ghrelin
  233. Ghrelin: update on a novel hormonal system
  234. Ghrelin exerts a proliferative effect on a rat pituitary somatotroph cell line via the mitogen-activated protein kinase pathway
  235. A Comparison of a Novel Testosterone Bioadhesive Buccal System, Striant, with a Testosterone Adhesive Patch in Hypogonadal Males
  236. Ghrelin?a hormone with multiple functions
  237. Elevated Fasting Plasma Ghrelin in Prader-Willi Syndrome Adults Is Not Solely Explained by Their Reduced Visceral Adiposity and Insulin Resistance
  238. Non-Growth Hormone Endocrine Actions of Ghrelin
  239. Identification of Adrenocorticotropin Receptor Messenger Ribonucleic Acid in the Human Pituitary and Its Loss of Expression in Pituitary Adenomas
  240. The Kruppel-like transcription factor 6 gene in sporadic pituitary tumours
  241. Reduced expression of the growth hormone and type 1 insulin‐like growth factor receptors in human somatotroph tumours and an analysis of possible mutations of the growth hormone receptor
  242. Rapid desensitisation of the GH secretagogue (ghrelin) receptor to hexarelin in vitro
  243. Activating point mutations in cyclin-dependent kinase 4 are not seen in sporadic pituitary adenomas, insulinomas or Leydig cell tumours
  244. Ghrelin is Released from Rat Hypothalamic Explants and Stimulates Corticotrophin-releasing Hormone and Arginine-vasopressin
  245. Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency
  246. Macrophage migration inhibitory factor expression is increased in pituitary adenoma cell nuclei
  247. Sequence analysis of the PRKAR1A gene in sporadic somatotroph and other pituitary tumours
  248. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  249. A Variation in the Ghrelin Gene Increases Weight and Decreases Insulin Secretion in Tall, Obese Children
  250. Cell Cycle Dysregulation in Human Pituitary Tumours
  251. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  252. Expression of Phosphorylated p27Kip1Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  253. Expression of Phosphorylated p27Kip1 Protein and Jun Activation Domain-Binding Protein 1 in Human Pituitary Tumors
  254. The Tissue Distribution of the mRNA of Ghrelin and Subtypes of Its Receptor, GHS-R, in Humans
  255. Optimal Response Criteria for the Human CRH Test in the Differential Diagnosis of ACTH-Dependent Cushing's Syndrome
  256. Response of Serum Macrophage Migration Inhibitory Factor Levels to Stimulation or Suppression of the Hypothalamo-Pituitary-Adrenal Axis in Normal Subjects and Patients with Cushing's Disease
  257. The Effect of Growth Hormone Secretagogues and Neuropeptide Y on Hypothalamic Hormone Release from Acute Rat Hypothalamic Explants
  258. The release of leptin and its effect on hormone release from human pituitary adenomas
  259. Expression of 11β-Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  260. Ghrelin, the endogenous ligand to the growth hormone secretagogue receptor — expression in human hypothalamus and pituitary
  261. Expression of 11 -Hydroxysteroid Dehydrogenase Isoenzymes in the Human Pituitary: Induction of the Type 2 Enzyme in Corticotropinomas and Other Pituitary Tumors
  262. Imprinting of the Gsα gene GNAS1 in the pathogenesis of acromegaly
  263. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors1
  264. Comparison of Somatostatin Analog and Meta-Iodobenzylguanidine Radionuclides in the Diagnosis and Localization of Advanced Neuroendocrine Tumors
  265. The Expression of the Growth Hormone Secretagogue Receptor Ligand Ghrelin in Normal and Abnormal Human Pituitary and Other Neuroendocrine Tumors
  266. Presence of Ghrelin in Normal and Adenomatous Human Pituitary
  267. How common are polycystic ovaries and the polycystic ovarian syndrome in women with Cushing's syndrome?
  268. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of theTrans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreasedα -Subunit Secretion1
  269. Expression of the Pituitary Transcription Factor Ptx-1, But Not That of the Trans-Activating Factor Prop-1, Is Reduced in Human Corticotroph Adenomas and Is Associated with Decreased  -Subunit Secretion
  270. Low Expression of the Cell Cycle Inhibitor p27Kip1in Normal Corticotroph Cells, Corticotroph Tumors, and Malignant Pituitary Tumors
  271. Hexarelin as a test of pituitary reserve in patients with pituitary disease
  272. The Growth Hormone Secretagogue Hexarelin Stimulates the Hypothalamo-Pituitary-Adrenal Axis via Arginine Vasopressin
  273. The growth hormone secretagogue receptor
  274. Expression of menin gene mRNA in pituitary tumours
  275. The Effects of GH-Secretagogues on Human Pituitary Cells in Culture and on Rat Hypothalamic Tissue
  276. Leptin and the thyroid — A puzzle with missing pieces
  277. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors1
  278. Expression of the Growth Hormone Secretagogue Receptor in Pituitary Adenomas and Other Neuroendocrine Tumors
  279. The Pathophysiology of Circulating Corticotropin-Releasing Hormone-Binding Protein Levels in the Human
  280. Leptin levels do not change acutely with food administration in normal or obese subjects, but are negatively correlated with pituitary‐adrenal activity
  281. Differential stimulation of corticol and dehydropiandrosterone levels by food in obese and normal subjects: relation to body fat distribution
  282. Intérêt clinique des neuropeptides GHRH et GHRP
  283. Diagnosis of Growth Hormone Deficiency in Adults
  284. The effect of an opiate antagonist on the hormonal changes induced by hexarelin
  285. Growth hormone-releasing peptide and its analogues
  286. Determination of Direct Effects of Cytokines on Release of Neuropeptides from Rat Hypothalamus by an in Vitro Method